

**Royal Stoke University Hospital** 

Data, Security and Protection Newcastle Road Stoke-on-Trent Staffordshire ST4 6QG

Email foi@uhnm.nhs.uk

Ref: FOIA Reference 2021/22-279

Date: 9th September 2021

## Dear

I am writing to acknowledge receipt of your email dated 19<sup>th</sup> August 2021 requesting information under the Freedom of Information Act (2000) regarding blood disorders.

As of 1<sup>st</sup> November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1 I have a freedom of information request related to the treatment of certain blood disorders. I would greatly appreciate if you could answer the following questions.

How many patients has your Trust treated (for any disease) in the last 6 months with the following treatments:

- Doptelet (avatrombopag)
- Jakavi (ruxolitinib)
- Nplate (romiplostim)
- Revolade (eltrombopag)
- Tavlesse (fostamatinib)
- Hydroxycarbamide
- A1 See below: Data shown for Feb 21 to July 21 (inclusive).
  - Doptelet (avatrombopag) = 0
  - Jakavi (ruxolitinib) = 7
  - Nplate (romiplostim) = 20
  - Revolade (eltrombopag) = 11
  - Taylesse (fostamatinib) = 0
  - Hydroxycarbamide = 169
- Q2 In the last 6 months, how many patients has your Trust treated for:
  - Immune thrombocytopenia (ICD10 code D69.3)
  - Myelofibrosis (ICD10 code D47.4)
  - Myelofibrosis (ICD10 code D47.4) patients over the age 65
- A2 Having reviewed the attached these ICD-10 codes are all 'D' codes which we do not capture on the Somerset Cancer Register. We only capture ICD-10 codes beginning with 'C' or 'D05'. Therefore this information is not held







- Q3 Of the patients treated for immune thrombocytopenia (ICD10 code D69.3) in the last 6 months, how many were treated with:
  - Mycophenolate mofetil
  - Rituximab
  - Surgery (splenectomy)
- A3 As answer 2
- Q4 How many myelofibrosis (ICD10 code D47.4) patients has your Trust diagnosed in the past 3 years?
  - Of the myelofibrosis patients diagnosed in the last 3 years, how many were treated in the past 6 months with Hydroxycarbamide?
  - Of the myelofibrosis patients diagnosed in the last 3 years, how many have received no active treatment in the past 6 months?
- A4 As answer 2
- Q5 Does you Trust participate in any on-going clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?
- A5 As answer 2
- Q6 Does you Trust participate in any on-going clinical trials for myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part?
- A6 None at present time

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <a href="http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/">http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/</a>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <a href="http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx">http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx</a>





<sup>\*</sup>Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.



This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via <a href="https://www.ico.org.uk">www.ico.org.uk</a>.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 671612.

Yours.

Jean Lehnert

**Data, Security & Protection Manager** 

on Cohnert



